Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license option ...

Advancing RNA therapeutics depends on understanding two critical questions: Where do drug candidates go, and what do they do ...

RNA molecules are an integral part of the human body: In cells, they ensure the transfer of genetic information and regulate the activity of genes. Some even act as catalysts, allowing chemical ...

A tiny chemical modification commonly found on messenger RNAs plays a surprisingly large role in how cells respond to stress, according to a study led by Weill Cornell Medicine investigators. The ...

New research from Dr. Seungjae Lee, Dr. Eric Lai, and their collaborators points to a potential opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially ...

LOS ANGELES--(BUSINESS WIRE)--Molecular Instruments® (MI), the inventor of the HCR™ platform, today announced key enhancements to its HCR™ Gold and HCR™ Pro product lines. These upgrades include ...

Arnatar Therapeutics has unveiled with $52 million in series A financing to bankroll new RNA-based therapies, including a candidate that takes aim at a rare genetic disease called Alagille syndrome ...

Researchers from the University of Eastern Finland and Aalto University have developed a computational framework called SegPore that enhances the accuracy of RNA modification detection from direct RNA ...

Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and ...